La chaîne d'options affiche les données clés des options sur actions de Seres Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Seres Therapeutics..

Seres Therapeutics (NASDAQ:MCRB) Stock, Chaîne d'Options

Seres Therapeutics

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Seres Therapeutics Inc

Earnings

Press Releases

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

News

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Health Care

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

General

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

Seres Therapeutics Announces Leadership Transition

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

MCRB

SANA

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

C4 Therapeutics

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Citius Oncology

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Elicio Therapeutics

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Forte Biosciences

Genfit

Genelux

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Nkarta

Nuvectis Pharma

PepGen

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tevogen Bio Holdings

Zura Bio Limited - Class A Ordinary shares

Comments

Seres Therapeutics

Seres Therapeutics (MCRB) Options

Seres Therapeutics (NASDAQ:MCRB) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL